Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days

Short name Gonapeptyl

NCTNCT01468441 (opens ClinicalTrials.gov in a new tab)Other idFert-LG-Doutorado
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Not applicable
Enrollment
96 participants (actual)
Sponsor
Fertility - Assisted Fertilization Center · Other
Design
Randomized · Single masking
Countries
1 country

Brazil

Start
Sept 2011
Primary completion
Mar 2012
Completion
Mar 2012
First posted
9 Nov 2011 (estimated)
Last update posted
13 Jul 2012 (estimated)
Conditions
Infertility

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201120122013
  1. N/A

    Gonapeptyl

    NCT01468441

    Sept 2011 to Mar 2012

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.

Interventions

  • TriptorelinDrug
  • CetrorelixDrug

Arms2

  • Experimental

    GnRH agonist

    Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.

  • Active comparator

    GnRH antagonist

    Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. cost of treatment

    Time frame · One month

Secondary outcomes(1)

  1. Implantation and pregnancy rates

    Time frame · 2 months

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2013

5 results

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments.

Maldonado et al. 2013Fertility and sterilitycited by 17

PMID 23394779DOI 10.1016/j.fertnstert.2013.01.095PUB-23394779

Full text at the publisher5 results
Publisher pageSee results (5)

Eligibility

Who could join, as posted.

Sex
Female
Age
up to 35 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * women of good physical and mental health * under 37 years old, with regular menstrual cycles of 25-35 days * normal basal FSH and LH levels * BMI less than 30 kg/m2 * presence of both ovaries and intact uterus * absence of polycystic ovaries * endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases * all patients signed a written informed consent form * no patient had received any hormone therapy for at least 60 days preceding the study.

PepBank is a research reference. Talk to a doctor before you use any peptide.